Kidney International Reports最新文献

{"title":"Exploring Angiopoietin-2: Clinical Insights and Experimental Perspectives in Kidney Diseases.","authors":"An-Jie Luo, Fan-Chi Chang, Shuei-Liong Lin","doi":"10.1016/j.ekir.2024.09.001","DOIUrl":"https://doi.org/10.1016/j.ekir.2024.09.001","url":null,"abstract":"<p><p>Angiopoietin-2, an important contributor to angiogenesis and vascular remodeling, is increasingly recognized in kidney research. This review explores clinical insights and experimental perspectives on angiopoietin-2 in kidney diseases. Traditionally seen as an antagonist of the Tie-2, which is a receptor tyrosine kinase of endothelial cells and some hematopoietic stem cells, angiopoietin-2 exerts both proangiogenic and antiangiogenic effects, making it a versatile and context-dependent player in kidney pathophysiology. Elevated circulating angiopoietin-2 levels in clinical scenarios are associated with sepsis and acute kidney injury (AKI), emphasizing its role as a biomarker of disease severity. In diabetic kidney disease, circulating angiopoietin-2 correlates with albuminuria, a crucial indicator of disease progression, and may serve as a treatment target in protecting the endothelium. Angiopoietin-2 is implicated in chronic kidney diseases (CKDs), where its elevated circulating levels correlate with kidney outcomes and cardiovascular complications, suggesting its potential impact on kidney function and overall health. In experimental settings, angiopoietin-2 plays a pivotal role in angiogenesis and lymphangiogenesis, influencing vascular stability and endothelial integrity. The context-dependent agonist and antagonist role of angiopoietin-2 is regulated by a Tie-2 phosphatase, vascular endothelial protein tyrosine phosphatase (VEPTP), further underscoring its complexity. Angiopoietin-2 is also involved in regulating cellular integrity, inflammation, and endothelial permeability, making it a promising therapeutic target for conditions characterized by disrupted endothelial junctions and vascular dysfunction. This review provides a comprehensive overview of the diverse roles of angiopoietin-2 in kidney research, offering insights into potential therapeutic targets and advancements in managing kidney diseases.</p>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 12","pages":"3375-3385"},"PeriodicalIF":5.7,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidney Biopsy Findings After Lung Transplantation","authors":"David de Saint Gilles ,&nbsp;Marion Rabant ,&nbsp;Aurélie Sannier ,&nbsp;Charlotte Mussini ,&nbsp;Alexandre Hertig ,&nbsp;Antoine Roux ,&nbsp;Alexandre Karras ,&nbsp;Eric Daugas ,&nbsp;Vincent Bunel ,&nbsp;Jerome Le Pavec ,&nbsp;Renaud Snanoudj","doi":"10.1016/j.ekir.2024.07.005","DOIUrl":"10.1016/j.ekir.2024.07.005","url":null,"abstract":"<div><h3>Introduction</h3><p>The early diagnosis of histological kidney damage after lung transplantation (LT) is of paramount importance given the negative prognostic implications of kidney disease.</p></div><div><h3>Methods</h3><p>Three pathologists analyzed all kidney biopsies (KBs) (N = 100) performed from 2010 to 2021 on lung transplant patients in 4 Paris transplantation centers.</p></div><div><h3>Results</h3><p>The main indication for biopsy was chronic renal dysfunction (72% of patients). Biopsies were performed at a median of 26.3 months after transplantation and 15 months after a decline in estimated glomerular filtration rate (eGFR) or the onset of proteinuria. Biopsies revealed a wide spectrum of chronic lesions involving the glomerular, vascular, and tubulointerstitial compartments. The 4 most frequent final diagnoses, observed in 18% to 49% of biopsies, were arteriosclerosis, acute calcineurin inhibitor (CNI) toxicity, thrombotic microangiopathy (TMA) and acute tubular necrosis (ATN). TMA was significantly associated with a combination of mTOR inhibitors (mTORi) or CNIs with biological signs present in only 50% of patients. The eGFR was poorly correlated with most lesions, particularly percent glomerulosclerosis, and with the risk of end-stage renal disease (ESRD). Thirty-four patients progressed to ESRD at an average of 20.1 months after biopsy. Three factors were independently associated with the risk of ESRD: postoperative dialysis, proteinuria &gt;3 g/g and percent glomerulosclerosis &gt;4%.</p></div><div><h3>Conclusion</h3><p>Given the great diversity of renal lesions observed in lung transplant recipients, early referral to nephrologists for KB should be considered for these patients when they present with signs of kidney disease.</p></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 9","pages":"Pages 2774-2785"},"PeriodicalIF":5.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468024924018217/pdfft?md5=bcd003313d11c16d92b32eb54ed67920&pid=1-s2.0-S2468024924018217-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141699697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"APOL1 High-Risk Genotype is Not Associated With New or Worsening of Proteinuria or Kidney Function Decline Following COVID-19 Vaccination","authors":"","doi":"10.1016/j.ekir.2024.06.023","DOIUrl":"10.1016/j.ekir.2024.06.023","url":null,"abstract":"<div><h3>Introduction</h3><p>SARS-CoV-2 infection increases systemic inflammatory cytokines which act as a second-hit driver of Apolipoprotein L1 (APOL1)-mediated collapsing glomerulopathy. SARS-CoV-2 vaccination also increases cytokines. Recent reports of new glomerular disease in individuals with <em>APOL1</em> high-risk genotype (HRG) following SARS-CoV-2 vaccination raised the concern SARS-CoV-2 vaccination may also act as a second-hit driver of APOL1-mediated glomerulopathy.</p></div><div><h3>Methods</h3><p>We screened 1507 adults in the Duke’s Measurement to Understand Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) registry and enrolled 105 eligible participants with available SARS-CoV-2 vaccination data, prevaccination and postvaccination serum creatinine, and urine protein measurements. Paired data were stratified by number of APOL1 risk alleles (RAs) and compared within groups using Wilcoxon signed rank test and across groups by analysis of variance.</p></div><div><h3>Results</h3><p>Among 105 participants, 30 (28.6%) had 2, 39 (37.1%) had 1, and 36 (34.3%) had 0 APOL1 RA. Most of the participants (94%) received at least 2 doses of vaccine. Most (98%) received the BNT162B2 (Pfizer) or mRNA-1273 (Moderna) vaccine. On average, the prevaccine and postvaccine laboratory samples were drawn 648 days apart. There were no detectable differences between pre- and post-serum creatinine or pre- and post-urine albumin creatinine ratio irrespective of the participants’ APOL1 genotype. Finally, most participants with APOL1 RA had the most common haplotype (E150, I228, and K255) and lacked the recently described protective N264K haplotype.</p></div><div><h3>Conclusion</h3><p>In this observational study, <em>APOL1</em> HRG is not associated with new or worsening of proteinuria or decline in kidney function following SARS-CoV-2 vaccination. Validation of this result in larger cohorts would further support the renal safety of SARS-CoV-2 vaccine in individuals with APOL1 HRG.</p></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 9","pages":"Pages 2657-2666"},"PeriodicalIF":5.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468024924017996/pdfft?md5=d3c49dbecbb47ba9f8c51ddac05179c5&pid=1-s2.0-S2468024924017996-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141553287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Keep Calm and Dialyze On: Debunking the Myths of Peritoneal Dialysis Leaks","authors":"Susan McGrath ,&nbsp;Arsh K Jain","doi":"10.1016/j.ekir.2024.07.022","DOIUrl":"10.1016/j.ekir.2024.07.022","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 9","pages":"Pages 2588-2590"},"PeriodicalIF":5.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468024924018527/pdfft?md5=9014fd5ae9724eb04c9d7537065b8645&pid=1-s2.0-S2468024924018527-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141839320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing and Modality of Kidney Replacement Therapy in Children and Adolescents","authors":"","doi":"10.1016/j.ekir.2024.06.009","DOIUrl":"10.1016/j.ekir.2024.06.009","url":null,"abstract":"<div><h3>Introduction</h3><p>The choice and timing of kidney replacement therapy (KRT) is influenced by clinical factors, laboratory features, feasibility issues, family preferences, and clinicians' attitudes. We analyzed the factors associated with KRT modality and timing in a multicenter, multinational prospective pediatric cohort study.</p></div><div><h3>Methods</h3><p>A total of 695 pediatric patients with chronic kidney disease (CKD) enrolled into the Cardiovascular Comorbidity in Children with CKD (4C) study at age 6 to 17 years with estimated glomerular filtration rate (eGFR) of 10 to 60 ml/min per 1.73 m² were investigated. Competing risk regression was performed to identify factors associated with initiation of dialysis or preemptive transplantation (Tx), including primary renal diagnosis, demographics, anthropometrics, and laboratory parameters.</p></div><div><h3>Results</h3><p>During the 8-year observation period, 342 patients (49%) started KRT. Of these, 200 patients started dialysis, whereas 142 patients underwent preemptive Tx. A lower eGFR at enrolment (Hazard ratio [HR]: 0.76 [95% confidence interval: 0.74–0.78]), a steeper eGFR slope (HR: 0.90 [0.85–0.95], and a higher systolic blood pressure SD score (SDS) (HR: 2.07 [1.49–2.87]) increased the likelihood of KRT initiation. Patients with glomerulopathies were more likely to start dialysis than children with congenital anomalies of the kidneys and urinary tracts (CAKUT) (HR: 3.81 [2.52–5.76]). Lower body mass index (BMI) SDS (HR: 0.73 [0.6–0.89]) and lower hemoglobin (HR: 0.8 [0.72–0.9]) were associated with higher likelihood of dialysis. A significant center effect was observed, accounting for 6.8% (dialysis) to 8.7% (preemptive Tx) of explained variation.</p></div><div><h3>Conclusion</h3><p>The timing and choice of KRT in pediatric patients is influenced by the rate of kidney function loss, the underlying kidney disease, nutritional status, blood pressure, anemia and center-specific factors.</p></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 9","pages":"Pages 2750-2758"},"PeriodicalIF":5.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468024924017686/pdfft?md5=0fab4bdd1dcafcbba82780a483e4d82d&pid=1-s2.0-S2468024924017686-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141407640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Novel Adverse Events of Nefecon","authors":"Jingyu Wang ,&nbsp;Zhao Zhang ,&nbsp;Xingzi Liu ,&nbsp;Sufang Shi ,&nbsp;Jicheng Lv ,&nbsp;Yuemiao Zhang ,&nbsp;Hong Zhang","doi":"10.1016/j.ekir.2024.07.006","DOIUrl":"10.1016/j.ekir.2024.07.006","url":null,"abstract":"<div><h3>Introduction</h3><p>Nefecon, the first innovative drug approved by both the US Food and Drug Administration (FDA) and European Medicines Agency for IgA nephropathy (IgAN), lacked comprehensive real-world assessments of its adverse events (AEs).</p></div><div><h3>Methods</h3><p>We leveraged postmarketing data of Nefecon from the US FDA Adverse Event Reporting System (FAERS), employing disproportionate analysis (DPA) to detect positive signals at the system organ class (SOC) and preferred terms (PTs) levels. Duplicate AEs related to budesonide and those previously reported in studies were excluded through the use of the Medical Dictionary of Regulatory Activities (MedDRA). Our analysis encompassed time-to-onset (TTO), Weibull shape parameter (WSP) evaluation, cumulative incidence, clinical prioritization evaluation, and subgroup analysis based on gender and age.</p></div><div><h3>Results</h3><p>A total of 1515 individuals with IgAN were included. Five positive SOC signals and 23 positive PT signals were identified, including 4 PTs (asthenia, malaise, product dose omission issue, and anxiety) representing novel AEs newly identified in this study. None of the positive PTs were classified as high clinical priority, with only acne, hypertension, swelling face, and weight increased considered as moderate clinical priority events. The median time to TTO was 31 days. All WSP test results indicated an early failure type profile. Lastly, subgroup analysis provided further insights into the relative risk of specific AEs.</p></div><div><h3>Conclusion</h3><p>Nefecon demonstrates a favorable safety profile, with no high-priority clinical events identified. The identification of novel AEs and subgroup-specific relative high-risk events fills a gap in existing studies and offers valuable insights for early clinical vigilance.</p></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 9","pages":"Pages 2705-2717"},"PeriodicalIF":5.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468024924018229/pdfft?md5=5ac9a3e7a4d438bb3976ce338e3f61aa&pid=1-s2.0-S2468024924018229-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141701368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Many Faces of Congenital Anomalies of the Kidney and Urinary Tract","authors":"Miriam Schmidts ,&nbsp;Md Abdul Qader","doi":"10.1016/j.ekir.2024.07.028","DOIUrl":"10.1016/j.ekir.2024.07.028","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 9","pages":"Pages 2594-2595"},"PeriodicalIF":5.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468024924018588/pdfft?md5=bca5339e482acbcd8b01448430a9b094&pid=1-s2.0-S2468024924018588-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141941212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations","authors":"","doi":"10.1016/j.ekir.2024.05.033","DOIUrl":"10.1016/j.ekir.2024.05.033","url":null,"abstract":"<div><p>Associations of chronic kidney disease (CKD) with metabolic syndrome and cardiovascular disease (CVD) have long been recognized. Until recently, such associations were mainly limited to interrelationships between either heart and kidney, heart and metabolic syndrome, or metabolic syndrome and kidney. It is the merit of the American Heart Association (AHA) to have set up a work group of cardiologists, endocrinologists, and nephrologists for the purpose of combining all 3 disorders in a single entity, as an appreciation of their pathophysiological interrelatedness. To this end, they proposed the term cardiovascular-kidney-metabolic (CKM) syndrome, which reflects multidirectional relationships among metabolic risk factors, CKD, and the cardiovascular system. Following a consensus approach in defining CKM with 5 stages, the work group subsequently developed new risk prediction equations, named predicting risk of CVD events (PREVENT) equations, which included estimated glomerular filtration rate (eGFR) and albuminuria as variables in addition to traditional cardiovascular and metabolic factors. Despite several limitations, this development is a major step forward in cardiovascular risk prediction. Its clinical application should translate into earlier, more appropriate treatment and prevention of CKM syndrome.</p></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 9","pages":"Pages 2608-2618"},"PeriodicalIF":5.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468024924017571/pdfft?md5=3c6a54741595a08a2910aaa0c6dd3cdc&pid=1-s2.0-S2468024924017571-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141413905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Masked Arginine Vasopressin Deficiency in a Kidney Transplant Recipient With Posttransplant Lymphoproliferative Disorder","authors":"Annie Liu ,&nbsp;Lakshmi Nayak ,&nbsp;Waihay J. Wong ,&nbsp;Inhye E. Ahn ,&nbsp;Naoka Murakami","doi":"10.1016/j.ekir.2024.06.029","DOIUrl":"10.1016/j.ekir.2024.06.029","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 9","pages":"Pages 2832-2834"},"PeriodicalIF":5.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468024924018060/pdfft?md5=12fb9cf9529c003c21de373440d5455b&pid=1-s2.0-S2468024924018060-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141785755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invisible Threat: How Air Pollution Fuels Primary Glomerular Disease","authors":"Arjunmohan Mohan ,&nbsp;Srinivasan Beddhu","doi":"10.1016/j.ekir.2024.07.023","DOIUrl":"10.1016/j.ekir.2024.07.023","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 9","pages":"Pages 2591-2593"},"PeriodicalIF":5.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468024924018539/pdfft?md5=602bb83f547b126678400de0f450c16c&pid=1-s2.0-S2468024924018539-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141848613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}